Format

Send to

Choose Destination
  • This is a preview / test site. Please update your PubMed URL to pubmed.gov.
See comment in PubMed Commons below
ACS Med Chem Lett. 2017 Sep 7;8(10):1093-1098. doi: 10.1021/acsmedchemlett.7b00296. eCollection 2017.

From PIM1 to PI3Kδ via GSK3β: Target Hopping through the Kinome.

Author information

  • 1Refractory Respiratory Inflammation DPU, GlaxoSmithKline R&D, Gunnels Wood Road, Stevenage, SG1 2NY, U.K.
  • 2Molecular Discovery Research, Biological Sciences, and Computational Chemistry, Platform Technology & Science, GlaxoSmithKline R&D, Gunnels Wood Road, Stevenage, SG1 2NY, U.K.

Abstract

Selective inhibitors of phosphoinositide 3-kinase delta are of interest for the treatment of inflammatory diseases. Initial optimization of a 3-substituted indazole hit compound targeting the kinase PIM1 focused on improving selectivity over GSK3β through consideration of differences in the ATP binding pockets. Continued kinase cross-screening showed PI3Kδ activity in a series of 4,6-disubstituted indazole compounds, and subsequent structure-activity relationship exploration led to the discovery of an indole-containing lead compound as a potent PI3Kδ inhibitor with selectivity over the other PI3K isoforms.

KEYWORDS:

PI3Kδ inhibitor; Phosphoinositide-3-kinase delta inhibitor; kinase cross-screening

PMID:
29057057
PMCID:
PMC5642016
[Available on 2018-10-12]
DOI:
10.1021/acsmedchemlett.7b00296
[PubMed]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for American Chemical Society
    Loading ...
    Support Center